top
Search terms
Results 1 - 10 of 43 - ordered by :
Pages: 1 2 3 4 5 ... 5
Ehjournal

Subclinical coronary artery disease in Swiss HIV-positive and HIV-negative persons In multivariable adjusted analysis, HIV-positive participants had a lower prevalence of calcified plaque than ...

European Heart Journal, Tarr, Philip E, Ledergerber, Bruno, Calmy, Alexandra, Doco-Lecompte, Thanh, Marzel, Alex, Weber, Rainer, Kaufmann, Philipp A, Nkoulou, René, Buechel, Ronny R, Kovari, Helen

Date : 14/06/2018 Item size : 347717 bytes
Ehjournal

The causality of plasma low-density lipoprotein-cholesterol (LDL-C) and reduced LDL receptor-mediated LDL uptake in the pathophysiology of ASCVD has been established beyond any reasonable doubt.3 For ...

European Heart Journal, Landmesser, Ulf, John Chapman, M., Farnier, Michel, Gencer, Baris, Gielen, Stephan, Hovingh, G. Kees, Lüscher, Thomas F., Sinning, David, Tokgözoğlu, Lale, Wiklund, ...

Date : 01/08/2017 Item size : 474391 bytes
Ehjournal

Novel biomarkers that accurately report the risk of cardiovascular events such as myocardial infarction have long been sought after. Technical advances in the sensitivity, precision, and throughput ...

European Heart Journal, McFadyen, James D., Meikle, Peter J., Peter, Karlheinz

Date : 01/07/2017 Item size : 114940 bytes
Ehjournal

Novel biomarkers that accurately report the risk of cardiovascular events such as myocardial infarction have long been sought after. Technical advances in the sensitivity, precision, and throughput ...

European Heart Journal, McFadyen, James D., Meikle, Peter J., Peter, Karlheinz

Date : 01/07/2017 Item size : 135445 bytes
Ehjournal

While the former focused on individuals considered healthy, the latter was designed to avoid future events in those who already had coronary artery disease, myocardial infarction, or stroke.1 ...

European Heart Journal, Lüscher, Thomas F.

Date : 14/06/2017 Item size : 220664 bytes
Ehjournal

The causality of plasma low-density lipoprotein-cholesterol (LDL-C) and reduced LDL receptor-mediated LDL uptake in the pathophysiology of ASCVD has been established beyond any reasonable doubt.3 For ...

European Heart Journal, Landmesser, Ulf, John Chapman, M., Farnier, Michel, Gencer, Baris, Gielen, Stephan, Hovingh, G. Kees, Lüscher, Thomas F., Sinning, David, Tokgözoğlu, Lale, Wiklund, ...

Date : 09/03/2017
Ehjournal

The causality of plasma low-density lipoprotein-cholesterol (LDL-C) and reduced LDL receptor-mediated LDL uptake in the pathophysiology of ASCVD has been established beyond any reasonable doubt.3 For ...

European Heart Journal, Landmesser, Ulf, John Chapman, M., Farnier, Michel, Gencer, Baris, Gielen, Stephan, Hovingh, G. Kees, Lüscher, Thomas F., Sinning, David, Tokgözoğlu, Lale, Wiklund, ...

Date : 08/03/2017 Item size : 424498 bytes
Ehjournal

Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are a new class of drugs able to decrease LDL-C by 5070% when administered either as a monotherapy or on a background with statins.46 ...

European Heart Journal, ISSUE @ A GLANCE, Thomas F. Lüscher

Date : 21/09/2015
Ehjournal

Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are a new class of drugs able to decrease LDL-C by 5070% when administered either as a monotherapy or on a background with statins.46 ...

European Heart Journal, Lüscher, Thomas F.

Date : 21/09/2015
Ehjournal

Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are a new class of drugs able to decrease LDL-C by 5070% when administered either as a monotherapy or on a background with statins.46 ...

European Heart Journal, Lüscher, Thomas F.

Date : 21/09/2015 Item size : 220026 bytes